Review Note
Last Update: 08/30/2023 12:42 AM
Current Deck: ACMS Study Guide Deck::A. Cancers
Published
Fields:
Front
45% of melanomas have activating mutations in ?
Back
45% of melanomas have activating mutations in BRAF
▪ Substitution of glutamic acid (E) for valine (V) at codon 600 (V600E) in
90% of BRAF mutations.
▪ Vemurafenib, dabrafenib, encorafenib target the mutant BRAF kinase
▪ Resistance is a concern
▪ Paradoxical activation of MAPK pathway in keratinocytes with wildtype BRAF and RAS mutations can lead to cutaneous SCCs and
keratoacanthomas in up to 25% of patients
▪ Now combined with MEK inhibitors (binimetinib, cobimetinib,
trametinib)
▪ Substitution of glutamic acid (E) for valine (V) at codon 600 (V600E) in
90% of BRAF mutations.
▪ Vemurafenib, dabrafenib, encorafenib target the mutant BRAF kinase
▪ Resistance is a concern
▪ Paradoxical activation of MAPK pathway in keratinocytes with wildtype BRAF and RAS mutations can lead to cutaneous SCCs and
keratoacanthomas in up to 25% of patients
▪ Now combined with MEK inhibitors (binimetinib, cobimetinib,
trametinib)
Tags:
Suggested Changes:
Deck Changes (Suggestion to move the Note to the following Deck):
Field Changes:
Tag Changes: